Showing results (1761-1770 of 2,001) with videos related to
Sort By:
Pageof 201
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2010
Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099Thomas J Lynch, Taral Patel, Luke Dreisbach, et al.Bioorganic & Medicinal Chemistry Letters|March 20, 2003
Novel 5-cyclopropyl-1,4-benzodiazepin-2-ones as potent and selective I(Ks)-blocking class III antiarrhythmic agentsJohn W Butcher, Nigel J Liverton, David A Claremon, et al.Chemico-Biological Interactions|June 9, 2001
Biomarkers for assessing occupational exposures to 1,3-butadieneR J Albertini, R J Sram, P M Vacek, et al.The Journal of Physical Chemistry. B|February 9, 2022
In Situ Determination of Speciation and Local Structure of NaCl-SrCl2 and LiF-ZrF4 Molten SaltsTimothy J Lynch, Nancy R Birkner, Matthew S Christian, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2009
Integration of molecular profiling into the lung cancer clinicWilliam Pao, Mark G Kris, A John Iafrate, et al.Cancer|August 10, 2000
Patterns of breast carcinoma treatment in older women: patient preference and clinical and physical influencesJ S Mandelblatt, J Hadley, J F Kerner, et al.Journal of Medicinal Chemistry|August 18, 1995
Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonistM E Duggan, A M Naylor-Olsen, J J Perkins, et al.Nanoscale|August 9, 2019
Sonochemical edge functionalisation of molybdenum disulfideAline Amorim Graf, Matthew J Large, Sean P Ogilvie, et al.Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|December 8, 1998
Cumulative incidence of colorectal and extracolonic cancers in MLH1 and MSH2 mutation carriers of hereditary nonpolyposis colorectal cancerK M Lin, M Shashidharan, A G Thorson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2010
Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancerLecia V Sequist, Benjamin Besse, Thomas J Lynch, et al.Pageof 201